Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort Article

Odia, Yazmin, Hall, Matthew D, Cloughesy, Timothy Francis et al. (2024). Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort . NEURO-ONCOLOGY, 26 S165-S172. 10.1093/neuonc/noae021

Open Access Industry Collaboration

cited authors

  • Odia, Yazmin; Hall, Matthew D; Cloughesy, Timothy Francis; Wen, Patrick Y; Arrillaga-Romany, Isabel; Daghistani, Doured; Mehta, Minesh P; Tarapore, Rohinton S; Ramage, Samuel C; Allen, Joshua E

sustainable development goals

authors

publication date

  • May 3, 2024

published in

keywords

  • CLINICAL-EFFICACY
  • Clinical Neurology
  • ClpP
  • DIFFUSE
  • DRD2
  • H3 K27M-mutant glioma
  • HIGH-GRADE GLIOMAS
  • Life Sciences & Biomedicine
  • NEUROONCOLOGY
  • Neurosciences & Neurology
  • ONC201
  • Oncology
  • RESPONSE ASSESSMENT
  • Science & Technology
  • non-midline H3 K27M-mutant glioma

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • S165

end page

  • S172

volume

  • 26